The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Probing the links between in vitro potency, ADMET and physicochemical parameters
Open accessAbstract
A common underlying assumption in current drug discovery strategies is that compounds with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics. This has led to the development of screening cascades with in vitro potency embedded as an early filter. However, this approach is beginning to be questioned, given the bias in physicochemical properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochemical parameters associated with high in vitro potency and those associated with desirable absorption, distribution, metabolism, excretion and toxicity (ADMET) characteristics. Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compounds. Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on average); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose. These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Self-citationGoh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Hopkins, A. L. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1110 · Cited by 1,242
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Self-citationMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
The maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Fourches, D., Muratov, E., & Tropsha, A. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100176x · Cited by 832
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups
Kalgutkar, A., Gardner, I., Obach, R., Shaffer, C., Callegari, E., Henne, K., Mutlib, A., Dalvie, D., Lee, J., Nakai, Y., et al. (2005) · Current Drug Metabolism · doi:10.2174/1389200054021799 · Cited by 616
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Functional group contributions to drug-receptor interactions
Andrews, P. R., Craik, D. J., & Martin, J. L. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00378a021 · Cited by 535
Simple Method of Calculating Octanol/Water Partition Coefficient.
MORIGUCHI, I., HIRONO, S., LIU, Q., NAKAGOME, I., & MATSUSHITA, Y. (1992) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.40.127 · Cited by 535
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Self-citationUsing the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Predicting protein druggability
Hajduk, P. J., Huth, J. R., & Tse, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03624-x · Cited by 289
Fragment-Based Drug Design: How Big Is Too Big?
Hajduk, P. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060511h · Cited by 265
Fragments, network biology and designing multiple ligands
Morphy, R., & Rankovic, Z. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204
Are the Chemical Structures in Your QSAR Correct?
Young, D., Martin, T., Venkatapathy, R., & Harten, P. (2008) · QSAR & Combinatorial Science · doi:10.1002/qsar.200810084 · Cited by 196
Daugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A.-C., Coste, H., Kirilovsky, J., Hyafil, F., & Labaudinière, R. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030056e · Cited by 195
Perola, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100118x · Cited by 188
Biological assay challenges from compound solubility: strategies for bioassay optimization
Di, L., & Kerns, E. H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.03.004 · Cited by 181
Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., & Urban, L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700036 · Cited by 176
Summerfield, S. G., Stevens, A. J., Cutler, L., del Carmen Osuna, M., Hammond, B., Tang, S.-P., Hersey, A., Spalding, D. J., & Jeffrey, P. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092916 · Cited by 175
Self-citationPeters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 156
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
Wunberg, T., Hendrix, M., Hillisch, A., Lobell, M., Meier, H., Schmeck, C., Wild, H., & Hinzen, B. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03700-1 · Cited by 152
Drug prototypes and their exploitation
(1997) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(97)84366-8 · Cited by 147
Assessment of the blood–brain barrier in CNS drug discovery
Jeffrey, P., & Summerfield, S. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.033 · Cited by 130
The evolution of synthetic oral drug properties
Proudfoot, J. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.024 · Cited by 129
McGinnity, D. F., Collington, J., Austin, R. P., & Riley, R. J. (2007) · Current Drug Metabolism · doi:10.2174/138920007780866799 · Cited by 128
Morphy, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512185 · Cited by 123
Receptor Occupancy and Brain Free Fraction
Watson, J. M., Wright, S., Lucas, A. J., Clarke, K. L., Viggers, J., Cheetham, S. C., Jeffrey, P., Porter, R. A., & Read, K. D. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022814 · Cited by 120
Lead-like, drug-like or “Pub-like”: how different are they?
Oprea, T. I., Allu, T. K., Fara, D. C., Curpan, R. F., Ostopovici, L., & Bologa, C. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9105-3 · Cited by 114
Components of Successful Lead Generation
Davis, A., Keeling, D., Steele, J., Tomkinson, N. P., & Tinker, A. C. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053828411 · Cited by 110
Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs
Vieth, M., & Sutherland, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603825 · Cited by 103
Janga, S. C., & Tzakos, A. G. (2009) · Molecular BioSystems · doi:10.1039/b908147j · Cited by 103
Molecular properties that influence oral drug-like behavior.
Lajiness, M. S., Vieth, M., & Erickson, J. A. (2004) · PubMed · Cited by 102
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Lackey, K. E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743156 · Cited by 92
Drug-like properties: guiding principles for design – or chemical prejudice?
Leeson, P. D., Davis, A. M., & Steele, J. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.11.005 · Cited by 82
Drug prototypes and their exploitation
(1997) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(97)90084-7 · Cited by 78
Peck, R. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.004 · Cited by 56
Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds
Tyrchan, C., Blomberg, N., Engkvist, O., Kogej, T., & Mureşan, S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.068 · Cited by 34
Cited by
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Self-citationQuantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Metadata
- Authors
- Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 197-208
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2083354933
- Cited by
- 503
- References
- 58
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.